Company / Current Liabilities
MBX Biosciences, Inc. Current Liabilities History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$11.1M
FY2024
5-year range
$3.9M / $11.1M
FY2023-FY2024
Trend
+181.5%
vs FY2023
Sector context
#205 of 213
Health Care
What the data says
Among 213 Health Care companies, MBX Biosciences, Inc. is in the top 4% for current liabilities.
Based on SEC 10-K filings.
$11M in FY2024.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $11.1M Sector average $1.6B
▼
-99.3% below sector average
Key checks
Key Insights
- In FY2024, current liabilities increased 181.5% year-over-year.
- Ranks #205 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.1M | +181.5% |
| FY2023 | $3.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026